About This Trial

BCMA-targeted ADC in combination with standard of care for myeloma.

Primary Endpoints

  • Progression-free survival
  • Overall response rate

Latest Update

February 2026

Primary analysis shows significant PFS improvement. Re-filing with FDA planned for Q2 2026.